Patient-reported outcomes (PROs) from the phase III IMbrave 150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) - Galle, P R; Finn, R S; Qin, S (Ann Oncol, 2019)